RxDoctor Payments Data

Josette Ragheb

Apple Valley, CANPI 1982849923

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $570,079 of the $570,379 with a category attached, or 99.9%. Alkermes, Inc. accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $374,169 and has fallen 51.1% since, to $182,921 in 2023.

$570,379in general payments, 2019–2025

Across 31 payments — averaging $18,399 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$570K
  • Agilent Technologies, Inc.$300
$1,731,886in research payments, 2019–2025

Across 111 payments — averaging $15,603 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ventana Medical Systems, Inc.$1.4M
  • GSK$355K

What the payments were for

  • Consulting fees$570,079100%
  • Travel & lodging$1460%
  • Food & beverage$1540%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alkermes, Inc.26$570,079
Agilent Technologies, Inc.5$300

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →